Pharmacokinetics, tissue distribution and excretion of a novel long-acting human insulin analogue – recombinant insulin LysArg in rats

References

• Achi, A. and Greenwood, R., 1998. Erythrocytes as oral delivery systems for human insulin. Drug development and industrial pharmacy, 24, 67–72.
   PubMed Web of Science ®Google Scholar
• Ashwell, S.G., Gebbie, J., and Home, P.D., 2006. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabetic medicine : a journal of the British Diabetic Association, 23, 879–886.
   PubMed Web of Science ®Google Scholar
• Birkeland, K.I., et al., 2011. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes care, 34, 661–665.
   PubMed Web of Science ®Google Scholar
• Bolli, G.B., et al., 2011. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetes, obesity & metabolism, 13, 251–257.
   PubMed Web of Science ®Google Scholar
• Chao, M., et al., 2010. Bioequivalence between two human insulin analogs in Chinese population: glulisine and lispro. Endocrine, 38, 48–52.
   PubMed Web of Science ®Google Scholar
• Dash, R.P., Babu, R.J., and Srinivas, N.R., 2018. Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus. Xenobiotica, 48, 89–108.
   PubMed Web of Science ®Google Scholar
• Evasio, P., et al., 2019. Effects of chronic exercise on gut microbiota and intestinal barrier in human with type 2 diabetes. Minerva Medica, 110, 3–11.
   PubMed Web of Science ®Google Scholar
• Garg, M.K., et al., 2014. Evaluation of surrogate markers for insulin resistance for defining metabolic syndrome in urban Indian adolescents. Indian pediatrics, 51, 279–284.
   PubMed Web of Science ®Google Scholar
• Garreton, S.A., 1972. The meaning of the discovery of insulin by Banting and Best in 1921. Revista médica de Chile, 100, 458–459.
   PubMedGoogle Scholar
• Heise, T., et al., 2016. Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action. Journal of diabetes, 8, 132–138.
   PubMed Web of Science ®Google Scholar
• Homko, C., et al., 2003. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care, 26, 2027–2031.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation, 2019. IDF Diabetes Atlas 9th Edition. Available from: https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/159:idf-diabetes-atlas-ninth-edition-2019.html
   Google Scholar
• Jayachandran, M., et al., 2018. Isoquercetin ameliorates hyperglycemia and regulates key enzymes of glucose metabolism via insulin signaling pathway in streptozotocin-induced diabetic rats. European journal of pharmacology, 829, 112–120.
   PubMed Web of Science ®Google Scholar
• Karamanou, M., et al., 2016. Milestones in the history of diabetes mellitus: the main contributors. World Journal of Diabetes, 7, 1–7.
   PubMed Web of Science ®Google Scholar
• Kruger, D.F. and Novak, L.M., 2019. Role of ultrafast-acting insulin analogues in the management of diabetes. Journal of the American Association of Nurse Practitioners, 31, 537–548.
   PubMed Web of Science ®Google Scholar
• Lawrence, R.D., 1939. Zinc-protamine-insulin in diabetes. British medical journal, 1, 1077–1080.
   PubMedGoogle Scholar
• Meex, R., Blaak, E., and Loon, L., 2019. Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes. Obesity reviews : an official journal of the International Association for the Study of Obesity, 20, 1205–1217.
   PubMed Web of Science ®Google Scholar
• Moser, E.G., Morris, A.A., and Garg, S.K., 2012. Emerging diabetes therapies and technologies. Diabetes research and clinical practice, 97, 16–26.
   PubMed Web of Science ®Google Scholar
• Müssig, K., et al. 2010. Diabetes, insulin, insulin analogues, and cancer. Deutsche medizinische Wochenschrift, 135, 924–929.
   PubMed Web of Science ®Google Scholar
• Nelson, R.W., Henley, K., and Cole, C.; the PZIR Clinical Study Group, 2009. Field safety and efficacy of protamine zinc recombinanthuman insulin for treatment of diabetes mellitus in cats. Journal of veterinary internal medicine, 23, 787–793.
   PubMed Web of Science ®Google Scholar
• Nucci, G. and Cobelli, C., 2000. Models of subcutaneous insulin kinetics. A critical review. Computer methods and programs in biomedicine, 62, 249–257.
   PubMed Web of Science ®Google Scholar
• Ola, M.S., 2014. Effect of hyperglycemia on insulin receptor signaling in the cultured retinal Müller glial cells. Biochemical and Biophysical Research Communications, 444, 264–269.
   PubMed Web of Science ®Google Scholar
• Plum, A., Agerso, H., and Andersen, L., 2000. Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, in rats, dogs, and pigs, and pharmacodynamics of insulin aspart in pigs. Drug metabolism and disposition : the biological fate of chemicals, 28, 155–160.
   PubMed Web of Science ®Google Scholar
• Rendell, M., 2013. Insulin degludec: a long-acting modern insulin analogue with a predictable pharmacokinetic/pharmacodynamic profile. Drugs today (Barcelona, Spain : 1998), 49, 387–397.
   PubMed Web of Science ®Google Scholar
• Rosenstock, J., et al., 2008. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia, 51, 408–416.
   PubMed Web of Science ®Google Scholar
• Takahara, M., et al., 2014. Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin. Diabetes technology & therapeutics, 16, 633–639.
   PubMed Web of Science ®Google Scholar
• Tibaldi, J.M., 2014. Evolution of insulin: from human to analog. The American journal of medicine, 127, S25–S38.
   PubMed Web of Science ®Google Scholar
• Timio, M., et al., 2003. Historical Archives of Italian Nephrology. Diabetic nephropathy and insulin discovery: two parallel histories. Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia, 20, 625–630.
   PubMedGoogle Scholar
• Uehata, K., et al., 2011. Effect of sulfobutyl ether-β-cyclodextrin on bioavailability of insulin glargine and blood glucose level after subcutaneous injection to rats. International journal of pharmaceutics, 419, 71–76.
   PubMed Web of Science ®Google Scholar
• Vora, J. and Heise, T., 2013. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review. Diabetes, obesity & metabolism, 15, 701–712.
   PubMed Web of Science ®Google Scholar
• Wang, F., Carabino, J.M., and Vergara, C.M., 2003. Insulin glargine: a systematie review of a long-acting insulin analogue. Clinical therapeutics, 25, 1541–1577.
   PubMed Web of Science ®Google Scholar
• Wang, J., et al., 2019. The effects of once-weekly dulaglutide and insulin glargine on glucose fluctuation in poorly oral-antidiabetic controlled patients with type 2 diabetes mellitus. BioMed research international, 2019, 1–8.
   Web of Science ®Google Scholar